Doubt it will be Shannon's call to downsize. She will be informed by Ops and/or some executive committee on what to do. Most sales force leaders are messengers, not deciders.
Wouldn’t be too surprising at this point. With such unattainable goals, the company wants blood from a stone from sales force. Looking at so many other factors like past shortages, compounding, formulary issues, AI, pressure from government to lower prices, consumers going to lilly direct etc… it impacts bottom line and time to cut opex?
Lilly will be launching Orforglipron next year, and Retatrutide in 2027, so the idea of layoffs when there are two drug launches on the horizon is much more "comical"..